Business Editors & Health/Medical Writers
ADVISORY...for FRIDAY (Feb. 22)
NOTE TO EDITORS: Multimedia Assets Available With This Story
Include Logos, Text News Releases, Video
The U.S. Food and Drug Administration (FDA) today approved the Novartis drug ZOMETA(R) (zoledronic acid for injection) for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy.
These solid tumors include prostate cancer, lung cancer, breast cancer and other solid tumor types. In prostate cancer, patients should have progressed after treatment with at least one hormonal therapy.
The trials that led to the approval of ZOMETA mark the first time any bisphosphonate has demonstrated efficacy in treating bone complications in patients with prostate cancer, lung cancer and other solid tumors.
Further, ZOMETA offers patients, nurses and clinicians a convenient 4 mg, 15-minute infusion time.
You can reach the story directly by going to http://www.newstream.com/cgi-bin/display_story.cgi?5185
This multimedia news story is for free and unrestricted use on your news information site (and for print or broadcast too). Visit http://www.newstream.com to download video, audio, text, graphics and photos.
If you have any questions about the story, or about Newstream.com, please write to us at firstname.lastname@example.org.
COPYRIGHT 2002 Business Wire
COPYRIGHT 2002 Gale Group